11/19/2013

A MarketsandMarkets report forecasts that the global biosimilars market will be worth $1.95 billion by 2018. Insulin, filgrastim and other recombinant protein products hold the biggest share of the market, but monoclonal antibodies are expected to be the fastest-growing segment. The Asia-Pacific region, which accounts for 29% of the global market, is forecast to grow the fastest, while the U.S. is waiting on the FDA to write regulations establishing a pathway for biosimilar reviews.

Full Story:
Drug Store News

Related Summaries